在DSS诱导的大肠炎中Ophiopogonin D的保护性质:洞察微生物群调节的洞察力
Tao Zhang1, Zhiguo Guo2, Xianhui Cheng3
1Department of Gastroenterology, Nanchong Central Hospital, The Second Clinical Medical College, North Sichuan Medical College, Nanchong, 637000, China. 305514271@qq.com.
Inflammopharmacology
|July 22, 2024
概括
奥菲奥波贡尼D通过改善肠道微生物群和减少炎症,有效治疗小鼠的性结肠炎. 这种天然化合物显示出作为这种慢性胃肠道疾病的治疗策略的希望.
科学领域:
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
- 微生物组研究 微生物组研究
背景情况:
- 性结肠炎 (UC) 是一个日益严重的全球健康问题.
- 来自Ophiopogon japonicus的Ophiopogonin D具有抗炎和抗氧化作用.
- 它在UC中的治疗作用尚未明确.
研究的目的:
- 在性结肠炎的小鼠模型中研究Ophiopogonin D的治疗潜力.
- 为了评估Ophiopogonin D对肠道炎症,透性和微生物群组成的影响.
主要方法:
- 使用了一种硫酸 (DSS) 诱导的大肠炎小鼠模型.
- 他们接受了Ophiopogonin D和propionic acid的治疗.
- 评估的参数包括体重减轻,便状况,结肠组织学,炎症标志物和肠道微生物群多样性.
主要成果:
- 奥菲奥波贡尼D显著缓解了DSS诱导的大肠炎症状,并改善了结肠的完整性.
- 治疗调节了关键的炎症标志物 (ZO-1,MUC-2,TNF-α,IL-1β).
- 奥菲奥波贡尼D改变了肠道微生物群,增加了阿克尔曼西亚和减少了Enterobacter;酸也显示了治疗益处.
结论:
- 在小鼠中,Ophiopogonin D对DSS诱导的大肠炎产生了显著的治疗作用.
- 这些效应与肠道微生物群和炎症通路的调节有关.
- 奥菲奥波贡尼D代表了性结肠炎治疗的潜在新型治疗剂.
相关概念视频
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
331
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
331
Drugs for Treatment of Diarrhea-Predominant IBS
156
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
156
Drugs for Treatment of Ulcerative Colitis in IBD
134
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
134
Inflammatory Bowel Disease IV: Pharmacological Management
124
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
124
Inflammatory Bowel Disease I: Ulcerative Colitis
160
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
160


